{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:38:50Z","timestamp":1772203130953,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"FI1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MundiPharma"},{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Healthcare"},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for Health Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims\u2003<\/jats:title>\n                  <jats:p>To compare the risk of all-cause mortality, stroke, and bleeding in patients with atrial fibrillation (AF) and valvular heart disease (VHD) treated with vitamin K antagonist (VKA) or factor Xa-inhibitors (FXa-I; rivaroxaban and apixaban).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results\u2003<\/jats:title>\n                  <jats:p>We cross-linked data from Danish nationwide registries identifying patients with AF and VHD (aortic stenosis\/insufficiency, mitral insufficiency, bioprosthetic heart valves, mitral-, and aortic valve repair) initiating VKA or FXa-I between January 2014 and June 2017. Outcomes were all-cause mortality, stroke, and bleeding. Using cause-specific Cox regression, we reported the standardized absolute 2-year risk of the outcomes and absolute risk differences (ARD). We identified 1115 (41.7%), 620 (23.1%), and 942 (35.2%) patients initiating treatment with VKA, rivaroxaban, and apixaban, respectively. The standardized absolute risk (95% confidence interval) of all-cause mortality associated with VKA treatment was 34.1% (30.4\u201337.8%) with corresponding ARD for FXa-I of \u22122.7% (\u22126.7% to 1.4%). The standardized absolute risk of stroke for VKA was 3.8% (2.2\u20135.4%) with corresponding ARD for FXa-I of \u20130.1% (\u22122.0% to 1.8%). The standardized risk of bleeding for VKA was 10.4% (7.2\u201312.9%) with corresponding ARD for FXa-I of \u20132.0% (\u22125.1% to 1.1%). The risk of bleeding was significantly reduced in subgroup analyses of apixaban compared with VKA [ARD: \u22123.9% (\u22127.0% to \u22120.9%)] and rivaroxaban [ARD: \u22125.6% (\u22129.5% to \u22121.7%)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion\u2003<\/jats:title>\n                  <jats:p>In this nationwide cohort study, there were no significant differences in the risks of all-cause mortality, stroke, and bleeding in patients with AF and VHD treated with VKA compared with FXa-I.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa011","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T12:09:48Z","timestamp":1581422988000},"page":"f93-f100","source":"Crossref","is-referenced-by-count":19,"title":["All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1803-5266","authenticated-orcid":false,"given":"Jarl Emanuel","family":"Strange","sequence":"first","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-3506","authenticated-orcid":false,"given":"Caroline","family":"Sindet-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Staerk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-0865","authenticated-orcid":false,"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Alexander","family":"Gerds","sequence":"additional","affiliation":[{"name":"Department of Public Health, Section of Biostatistics, University of Copenhagen, Oester Farimagsgade 5, Entrance B, 2nd floor, 1014 Copenhagen, Denmark"},{"name":"The Danish Heart Foundation, Vognmagergade 7, 1120 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Research, Nordsjaellands Hospital, Kongens Vaenge 2, 3400 Hilleroed, Denmark"},{"name":"Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar H","family":"Gislason","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark"},{"name":"The Danish Heart Foundation, Vognmagergade 7, 1120 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Noerre Alle 20, 2200 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas Bjerring","family":"Olesen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Post 635, Kildegaardsvej 28, 2900 Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"2021040921531185300_pvaa011-B1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2021040921531185300_pvaa011-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021040921531185300_pvaa011-B3","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u2018valvular\u2019 atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"2021040921531185300_pvaa011-B4","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/01.STR.31.11.2628","article-title":"Predictors of cerebrovascular events and death among patients with valvular heart disease: a population-based study","volume":"31","author":"Petty","year":"2000","journal-title":"Stroke"},{"key":"2021040921531185300_pvaa011-B5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"2021040921531185300_pvaa011-B6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ehjcvp\/pvx028","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis","volume":"4","author":"Caldeira","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021040921531185300_pvaa011-B7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021040921531185300_pvaa011-B8","doi-asserted-by":"crossref","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","article-title":"Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021040921531185300_pvaa011-B9","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"2021040921531185300_pvaa011-B10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"2021040921531185300_pvaa011-B11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"2021040921531185300_pvaa011-B12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021040921531185300_pvaa011-B13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijcard.2016.02.005","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease","volume":"209","author":"Noseworthy","year":"2016","journal-title":"Int J Cardiol"},{"key":"2021040921531185300_pvaa011-B14","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2021040921531185300_pvaa011-B15","doi-asserted-by":"crossref","first-page":"e008773","DOI":"10.1161\/JAHA.118.008773","article-title":"Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease","volume":"7","author":"Briasoulis","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2021040921531185300_pvaa011-B16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"2021040921531185300_pvaa011-B17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"2021040921531185300_pvaa011-B18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2021040921531185300_pvaa011-B19","first-page":"798","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Pottegard","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2021040921531185300_pvaa011-B20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000102143","article-title":"Validity of stroke diagnoses in a National Register of Patients","volume":"28","author":"Krarup","year":"2007","journal-title":"Neuroepidemiology"},{"key":"2021040921531185300_pvaa011-B21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021040921531185300_pvaa011-B22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1214\/13-STS453","article-title":"Standardization and control for confounding in observational studies: a historical perspective","volume":"29","author":"Keiding","year":"2014","journal-title":"Stat Sci"},{"key":"2021040921531185300_pvaa011-B23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2307\/2532098","article-title":"Estimates of absolute cause-specific risk in cohort studies","volume":"46","author":"Benichou","year":"1990","journal-title":"Biometrics"},{"key":"2021040921531185300_pvaa011-B24","first-page":"907","article-title":"Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study","volume":"38","author":"Staerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2021040921531185300_pvaa011-B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk","year":"2018","journal-title":"J Intern Med"},{"key":"2021040921531185300_pvaa011-B26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcpt.13024","article-title":"Use of non-vitamin K antagonist oral anticoagulants 2008-2016: a Danish Nationwide Cohort Study","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2021040921531185300_pvaa011-B27","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"2021040921531185300_pvaa011-B28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA Pilot Study","volume":"16","author":"Duraes","year":"2016","journal-title":"Drugs R D"},{"key":"2021040921531185300_pvaa011-B29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1160\/TH15-02-0116","article-title":"Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry","volume":"114","author":"Michalski","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa011\/32501535\/pvaa011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/FI1\/f93\/37011110\/pvaa011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/FI1\/f93\/37011110\/pvaa011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T21:55:49Z","timestamp":1618005349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/FI1\/f93\/5739442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":29,"journal-issue":{"issue":"FI1","published-online":{"date-parts":[[2020,2,17]]},"published-print":{"date-parts":[[2021,4,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa011","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,2,17]]}}}